Compounds > capuramycin
Page last updated: 2024-11-11

capuramycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

capuramycin: from Streptomyces griseus 446-S3; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5487121
CHEMBL ID96695
SCHEMBL ID14598937
MeSH IDM0142975

Synonyms (25)

Synonym
CHEMBL96695 ,
brn 5210055
446s3-1
antibiotic 446s3-1
beta-d-allofuranuronamide, 1-deoxy-5-o-(4-deoxy-n-(hexahydro-2-oxo-1h-azepin-3-yl)-beta-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-, (s)-
(6-{(1r)[(2s,3s,4r,5r)-5-(2,4-dioxo(1,3-dihydropyrimidinyl))-4-hydroxy-3-methoxyoxolan-2-yl]carbamoylmethoxy}(4s,5s,6s)-4,5-dihydroxy(4h-5,6-dihydropyran-2-yl))-n-((3s)-2-oxoazaperhydroepin-3-yl)carboxamide
(2s,3s,4s)-2-[(1r)-2-amino-1-[(2s,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-3-methoxy-tetrahydrofuran-2-yl]-2-oxo-ethoxy]-3,4-dihydroxy-n-[(3s)-2-oxoazepan-3-yl]-3,4-dihydro-2h-pyran-6-carboxamide
capuramycin
102770-00-3
bdbm50135599
(4s,5s,6s)-6-{(r)-carbamoyl-[(2s,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-hydroxy-3-methoxy-tetrahydro-furan-2-yl]-methoxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylic acid ((s)-2-oxo-azepan-3-yl)-amide
a-500359 b
(2s,3s,4s)-2-[(1r)-2-amino-1-[(2s,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-3-methoxyoxolan-2-yl]-2-oxoethoxy]-3,4-dihydroxy-n-[(3s)-2-oxoazepan-3-yl]-3,4-dihydro-2h-pyran-6-carboxamide
624x0oxy6y ,
unii-624x0oxy6y
SCHEMBL14598937
.alpha.-l-talofuranuronamide, 1-deoxy-5-o-(4-deoxy-n-(hexahydro-2-oxo-1h-azepin-3-yl)-.beta.-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-, (s)-
a-500359b
.alpha.-l-talofuranuronamide, 1-deoxy-5-o-(4-deoxy-n-((3s)-hexahydro-2-oxo-1h-azepin-3-yl)-.beta.-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-
1-deoxy-5-o-(4-deoxy-n-((3s)-hexahydro-2-oxo-1h-azepin-3-yl)-.beta.-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-.alpha.-l-talofuranuronamide
NKM ,
(2~{s},3~{s},4~{s})-2-[(1~{r})-2-azanyl-1-[(2~{s},3~{s},4~{r},5~{r})-5-[2,4-bis(oxidanylidene)pyrimidin-1-yl]-3-methoxy-4-oxidanyl-oxolan-2-yl]-2-oxidanylidene-ethoxy]-3,4-bis(oxidanyl)-~{n}-[(3~{s})-2-oxidanylideneazepan-3-yl]-3,4-dihydro-2~{h}-pyran-6-c
(2s,3s,4s)-2-{(1r)-2-amino-1-[(2s,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl]-2-oxoethoxy}-3,4-dihydroxy-n-[(3s)-2-oxoazepan-3-yl]-3,4-dihydro-2h-pyran-6-carboxamide (non-preferred name)
DTXSID501318180
(2s,3s,4s)-2-((r)-2-amino-1-((2s,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-n-((s)-2-oxoazepan-3-yl)-3,4-dihydro-2h-pyran-6-carboxamide

Research Excerpts

Actions

ExcerptReferenceRelevance
"Capuramycin displays a narrow spectrum of antibacterial activity by targeting bacterial translocase I (MraY). "( DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
Clemons, WM; Gillman, CD; Glazer, ES; Hevener, KE; Hussain, SM; Kansal, RG; Kurosu, M; Miranda-Carboni, GA; Mitachi, K; Yun, HG, 2020)		2.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12IC50 (µMol)0.01800.01800.01800.0180AID210950
Phospho-N-acetylmuramoyl-pentapeptide-transferaseStaphylococcus aureusIC50 (µMol)0.33000.02200.17600.3300AID1917609
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
regulation of cell shapePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
peptidoglycan biosynthetic processPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell divisionPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell wall organizationPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
cell wall macromolecule biosynthetic processPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
UDP-N-acetylglucosamine metabolic processUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
protein N-linked glycosylationUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
dolichol-linked oligosaccharide biosynthetic processUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
phospho-N-acetylmuramoyl-pentapeptide-transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
phosphotransferase activity, for other substituted phosphate groupsPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
metal ion bindingPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine:undecaprenyl-phosphate transferase activityPhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activityUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activityUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
protein bindingUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
glycosyltransferase activityUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
identical protein bindingUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
metal ion bindingUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
plasma membranePhospho-N-acetylmuramoyl-pentapeptide-transferaseEscherichia coli K-12
endoplasmic reticulum membraneUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
membraneUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
intracellular membrane-bounded organelleUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
membraneUDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1917618Antibacterial activity against Pseudomonas aeruginosa2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID143695Antimycobacterial activity against Mycobacterium avium (NIHJ1605)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
AID144144Antimycobacterial activity against Mycobacterium kansasii ATCC 124782003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID1696856Cytotoxicity in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917609Inhibition of Staphylococcus aureus MraY assessed as reduction of dansylated lipid I formation using UDP-MurNAc-dansylpentapeptide as substrate incubated for 3 to 4 hrs by fluorescence based analysis2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID143696Antimycobacterial activity against Mycobacterium avium NIHJ16052003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID1696851Cytotoxicity in human SiHa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID210950Inhibitory activity against translocase I2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
AID144441Antimycobacterial activity against Mycobacterium smegmatis (SANK 75075)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
AID1696854Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID144031Antimycobacterial activity against Mycobacterium intracellular ATCC 1954 E-32003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID1696848Inhibition of human DPAGT1 expressed in HEK293 (Expi293) cells incubated for 2 hrs using UDP-GlcN-Cg-FITC and alpha-dihydroundecap-renyl phosphate by reversed-phase HPLC analysis2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917611Antibacterial activity against Mycobacterium smegmatis mc2 155 incubated for 4 days measured by microplate reader method2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID144143Antimycobacterial activity against Mycobacterium kansasii (ATCC12478)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
AID1696852Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917607Inhibition of bacterial MraY2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1917615Antibacterial activity against Staphylococcus aureus2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696858Cytotoxicity in human hTERT-HPNE cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917610Antibacterial activity against Mycobacterium tuberculosis H37Rv incubated for 14 days measured by microplate reader method2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696853Cytotoxicity in human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917608Antibacterial activity against Mycobacterium smegmatis2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696859Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917619Antibacterial activity against Enterobacter species2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696857Cytotoxicity in human PD002 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID210953Inhibitory concentration against translocase-I2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID1917616Antibacterial activity against Klebsiella pneumoniae2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696849Cytotoxicity in human L1210 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1696847Inhibition of N-terminal His9-tagged Methanocaldococcus jannaschii DSM 2661 AglH incubated for 2 hrs using UDP-GlcN-Cg-FITC and alpha-dihydroundecap-renyl phosphate by reversed-phase HPLC analysis2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917612Antibacterial activity against Mycobacterium avium subsp. avium ATCC 25291 incubated for 11 days measured by microplate reader method2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696855Cytotoxicity in human PANC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1696842Inhibition of N-terminal 6x-His-tagged Hydrogenivirga-sp. 128-5-R1-1 MraY expressed in Escherichia coli NiCo21(DE3) incubated for 2 hrs by reversed-phase HPLC analysis2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917613Antibacterial activity against Mycobacterium abscessus subsp. abscessus ATCC 19977 incubated for 5 days measured by microplate reader method2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID1696850Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID1917614Antibacterial activity against Enterococcus faecium2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
AID144442Antimycobacterial activity was determined against Mycobacterium smegmatis SANK750752003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID1696846Inhibition of Escherichia coli WecA incubated for 2 hrs using UDP-Glucosamine-C6-FITC substrate by by reversed-phase HPLC analysis2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
AID144030Antimycobacterial activity against Mycobacterium intracellular (ATCC 1954 E-3)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.
AID1917617Antibacterial activity against Acinetobacter baumannii2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.45)18.7374
1990's0 (0.00)18.2507
2000's12 (41.38)29.6817
2010's13 (44.83)24.3611
2020's3 (10.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.58 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyridoxal phosphate
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.		7.6920methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.4220carbohydrazideantitubercular agent;
drug allergen
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		7.1310aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
uridine
[no description available]		8.5580uridinesdrug metabolite;
fundamental metabolite;
human metabolite
uridine monophosphate
Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.		2.1110pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		2.1110amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.2110arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
caprolactam
Caprolactam: Cyclic amide of caproic acid used in manufacture of synthetic fibers of the polyamide type. Can cause local irritation.. epsilon-caprolactam : A member of the class of caprolactams that is azepane substituted by an oxo group at position 2.		2.5220caprolactamshuman blood serum metabolite
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.0510ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		2.0510alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.2510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.2510organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
tocophersolan
tocophersolan: RN given refers to parent cpd		2.0510tocol
cobalt
Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.		2.0310cobalt group element atom;
metal allergen		micronutrient
sq-641
SQ-641: a MurX inhibitor with antitubercular activity; structure in first source		7.7630
cobaltous chloride
cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.		2.0310cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator
acebutolol
alpha-D-glucosyl-(1->4)-alpha-D-mannose : An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.		2.0310alpha-D-glucosyl-(1->4)-D-mannopyranose
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		2.1110
cpzen-45
CPZEN-45: caprazamycin derivative; structure in first source		2.2510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.4220cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.2510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.7430
Antibiotic-Associated Colitis
[description not available]		02.1310
Enterocolitis, Pseudomembranous
An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.		02.1310
Koch's Disease
[description not available]		02.0510
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		07.0510
Infections, Mycobacterium
[description not available]		02.0510
Mycobacterium Infections
Infections with bacteria of the genus MYCOBACTERIUM.		02.0510
Pulmonary Consumption
[description not available]		02.0210
Infection, Mycobacterium avium-intracellulare
[description not available]		02.0210
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		02.0210
Mycobacterium avium-intracellulare Infection
A nontuberculous infection when occurring in humans. It is characterized by pulmonary disease, lymphadenitis in children, and systemic disease in AIDS patients. Mycobacterium avium-intracellulare infection of birds and swine results in tuberculosis.		02.0210